Cargando…

Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032

BACKGROUND: BRAFV600E mutation is the most common mutation in thyroid cancer. It strongly activates MAPK/ERK pathway and indicates an invasive subtype of thyroid cancer. PLX4032 is a selective oral inhibitor of the BRAFV600 kinase although with limited effect in treating this panel of thyroid cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Su, Xi, Li, Peng, Han, Bin, Jia, Hao, Liang, Qingzhuang, Wang, Haichao, Gu, Mengwei, Cai, Jiaxuan, Li, Shaolei, Zhou, Yaqi, Yi, Xin, Wei, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816401/
https://www.ncbi.nlm.nih.gov/pubmed/33468157
http://dx.doi.org/10.1186/s13046-021-01831-y
_version_ 1783638435371679744
author Su, Xi
Li, Peng
Han, Bin
Jia, Hao
Liang, Qingzhuang
Wang, Haichao
Gu, Mengwei
Cai, Jiaxuan
Li, Shaolei
Zhou, Yaqi
Yi, Xin
Wei, Wei
author_facet Su, Xi
Li, Peng
Han, Bin
Jia, Hao
Liang, Qingzhuang
Wang, Haichao
Gu, Mengwei
Cai, Jiaxuan
Li, Shaolei
Zhou, Yaqi
Yi, Xin
Wei, Wei
author_sort Su, Xi
collection PubMed
description BACKGROUND: BRAFV600E mutation is the most common mutation in thyroid cancer. It strongly activates MAPK/ERK pathway and indicates an invasive subtype of thyroid cancer. PLX4032 is a selective oral inhibitor of the BRAFV600 kinase although with limited effect in treating this panel of thyroid cancer, due to the feedback activation of MAPK/ERK as well as PI3K/AKT pathways. It was investigated that Vitamin C plays a positive role in inhibiting these pathways in thyroid cancer. However, whether Vitamin C could enhance the antitumor effect of PLX4032 remains largely unclear. METHODS: The antitumor efficacy of combination therapy with PLX4032 and Vitamin C on BRAF(MT) thyroid cancer cell was assessed by the MTT assay, EdU assay and colony formation, Chou-Talalay way was employed to analyze the synergistic effect. Flow cytometry were employed to assess cells’ apoptosis and cell cycle arrest in response to combination therapy. Xenograft models were used to test its in vivo antitumor activity. Western blot and IHC were applied to investigate the mechanism underlying synergistic effect. RESULTS: PLX4032 or Vitamin C monotherapy was mildly effective in treating BRAF(MT) thyroid cancer cell and xenografts model. The combination therapy significantly inhibited cancer cell proliferation and tumor growth in nude mice, and induced cell apoptosis and cell cycle arrest compared to either monotherapy. PLX4032 monotherapy induced feedback activation of MAPK/ERK as well as PI3K/AKT pathway; while combination therapy significantly relieved this feedback. CONCLUSION: Vitamin C promotes the antitumor effect of PLX4032 in BRAF(MT) thyroid cancer cell and xenografts model via relieving the feedback activation of MAPK/ERK as well as PI3K/AKT pathway. PLX4032/Vitamin C combination may be a potential therapeutic approach to treat BRAF(MT) thyroid cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01831-y.
format Online
Article
Text
id pubmed-7816401
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78164012021-01-21 Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032 Su, Xi Li, Peng Han, Bin Jia, Hao Liang, Qingzhuang Wang, Haichao Gu, Mengwei Cai, Jiaxuan Li, Shaolei Zhou, Yaqi Yi, Xin Wei, Wei J Exp Clin Cancer Res Research BACKGROUND: BRAFV600E mutation is the most common mutation in thyroid cancer. It strongly activates MAPK/ERK pathway and indicates an invasive subtype of thyroid cancer. PLX4032 is a selective oral inhibitor of the BRAFV600 kinase although with limited effect in treating this panel of thyroid cancer, due to the feedback activation of MAPK/ERK as well as PI3K/AKT pathways. It was investigated that Vitamin C plays a positive role in inhibiting these pathways in thyroid cancer. However, whether Vitamin C could enhance the antitumor effect of PLX4032 remains largely unclear. METHODS: The antitumor efficacy of combination therapy with PLX4032 and Vitamin C on BRAF(MT) thyroid cancer cell was assessed by the MTT assay, EdU assay and colony formation, Chou-Talalay way was employed to analyze the synergistic effect. Flow cytometry were employed to assess cells’ apoptosis and cell cycle arrest in response to combination therapy. Xenograft models were used to test its in vivo antitumor activity. Western blot and IHC were applied to investigate the mechanism underlying synergistic effect. RESULTS: PLX4032 or Vitamin C monotherapy was mildly effective in treating BRAF(MT) thyroid cancer cell and xenografts model. The combination therapy significantly inhibited cancer cell proliferation and tumor growth in nude mice, and induced cell apoptosis and cell cycle arrest compared to either monotherapy. PLX4032 monotherapy induced feedback activation of MAPK/ERK as well as PI3K/AKT pathway; while combination therapy significantly relieved this feedback. CONCLUSION: Vitamin C promotes the antitumor effect of PLX4032 in BRAF(MT) thyroid cancer cell and xenografts model via relieving the feedback activation of MAPK/ERK as well as PI3K/AKT pathway. PLX4032/Vitamin C combination may be a potential therapeutic approach to treat BRAF(MT) thyroid cancer. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-021-01831-y. BioMed Central 2021-01-19 /pmc/articles/PMC7816401/ /pubmed/33468157 http://dx.doi.org/10.1186/s13046-021-01831-y Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Su, Xi
Li, Peng
Han, Bin
Jia, Hao
Liang, Qingzhuang
Wang, Haichao
Gu, Mengwei
Cai, Jiaxuan
Li, Shaolei
Zhou, Yaqi
Yi, Xin
Wei, Wei
Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
title Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
title_full Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
title_fullStr Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
title_full_unstemmed Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
title_short Vitamin C sensitizes BRAF(V600E) thyroid cancer to PLX4032 via inhibiting the feedback activation of MAPK/ERK signal by PLX4032
title_sort vitamin c sensitizes braf(v600e) thyroid cancer to plx4032 via inhibiting the feedback activation of mapk/erk signal by plx4032
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7816401/
https://www.ncbi.nlm.nih.gov/pubmed/33468157
http://dx.doi.org/10.1186/s13046-021-01831-y
work_keys_str_mv AT suxi vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032
AT lipeng vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032
AT hanbin vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032
AT jiahao vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032
AT liangqingzhuang vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032
AT wanghaichao vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032
AT gumengwei vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032
AT caijiaxuan vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032
AT lishaolei vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032
AT zhouyaqi vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032
AT yixin vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032
AT weiwei vitamincsensitizesbrafv600ethyroidcancertoplx4032viainhibitingthefeedbackactivationofmapkerksignalbyplx4032